Share

June 2014; 1 (1) ArticleOpen Access

AQP4 autoantibody assay performance in clinical laboratory service

J.P. Fryer, V.A. Lennon, S.J. Pittock, S.M. Jenkins, P. Fallier-Becker, S.L. Clardy, E. Horta, E.A. Jedynak, C.F. Lucchinetti, E.A. Shuster, B.G. Weinshenker, D.M. Wingerchuk, A. McKeon
First published May 22, 2014, DOI: https://doi.org/10.1212/NXI.0000000000000011
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1313

Share

Article Information

vol. 1 no. 1 e11
DOI: 
https://doi.org/10.1212/NXI.0000000000000011
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received January 20, 2014
  • Accepted in final form March 31, 2014
  • First Published May 22, 2014.
Copyright & Usage: 
© 2014 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. J.P. Fryer, MS,
    2. V.A. Lennon, MD, PhD,
    3. S.J. Pittock, MD,
    4. S.M. Jenkins, MS,
    5. P. Fallier-Becker, PhD,
    6. S.L. Clardy, MD, PhD,
    7. E. Horta, MD,
    8. E.A. Jedynak, BS,
    9. C.F. Lucchinetti, MD,
    10. E.A. Shuster, MD,
    11. B.G. Weinshenker, MD,
    12. D.M. Wingerchuk, MD and
    13. A. McKeon, MD
  1. J.P. Fryer, MS,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. V.A. Lennon, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Lennon and Mayo Clinic have a financial interest in the following intellectual property:

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. Dr. Lennon is Director of the Mayo Neuroimmunology Laboratory that performs service testing for aquaporin-4 autoantibodies on behalf of Mayo Collaborative Service Inc., an agency of Mayo Foundation. Neither Dr. Lennon nor her laboratory benefit financially from this testing.

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R01-NS065829,�CNS Demyelinating Autoimmunity Targeting Water Channel Complexes�. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Dr. Lennon has a potential financial interest in the technologies listed below:

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. S.J. Pittock, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Pittock and Mayo Clinic have a financial interest in the technology entitled

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Pittock has provided consultation to Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Pittock has received a research grant from Alexion pharmaceuticals for his investigator-initiated study entitled

    Research Support, Government Entities:

    1. RO1 NS065829-01 entitled �CNS Demyelinating Autoimmunity Targeting Water Channel Complexes�

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation grant for NMO research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. S.M. Jenkins, MS,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. P. Fallier-Becker, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. S.L. Clardy, MD, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. E. Horta, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis International Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. E.A. Jedynak, BS,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. C.F. Lucchinetti, MD,
    10. Scientific Advisory Boards:

    1. (1)Member NIH/NINDS CNBT Study Section

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen Idec, travel expense reimbursement, to present at their offices on May 10, 2013; honorarium and travel reimbursement to present on March 31, 2014

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) patent re: aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica

    Publishing Royalties:

    1. (1)Blue Books of Neurology: Multiple Sclerosis 3 (Saunders Elsevier, 2010)

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen Idec, 5-10-2013, travel reimbursement only Biogen Idec, 3-31-2014 travel reimb and honorarium

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH R01 NS049577-04: �Mechanisms of Multiple Sclerosis Tissue Pathology�(4/09-3/13) (2) NIH: 2P50 NS038667-11 �Tissue injury and inflammation in MS� Principal Investigator: Ransohoff RM (Cleveland Clinic Foundation); Co-Leader, Project 1 (Chemokines and chemokine receptors in MS): Lucchinetti CF. Category I: 5% (12/01/09-11/30/14). DoD (Co-investigator) Cortical Lesions as Determinants of White Matter Lesion Formation and Cognitive Abnormalities in MS 9/2013-8/2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) National Multiple Sclerosis Society: Multiple Sclerosis Lesion Project, RG3185-B-3. (No-cost extension) Principal Investigator: Lucchinetti CF. (4/1/05-9/30/10).(2)Guthy Jackson Charitable Foundation FP00052074 �Development and Validation of Aquaporin Autoimmunity Models� Principal Investigator: Lennon VA; Co-investigator: Lucchinetti CF. Category I: 8% (10/1/08- 09/30/11). (3) Guthy-Jackson Charitable Foundation, Synergistic Interactions between Astrocytes, Eosinophils and AQP4-IgG in NMO. ( 07/01/10 � 06/30/14)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica;

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. E.A. Shuster, MD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. PRIME, Inc., educational event, September, 2012. Personal compensation.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. B.G. Weinshenker, MD,
    12. Scientific Advisory Boards:

    1. (1) Novartis data safety monitoring board member (2) Biogen Idec data safety monitoring board member (3) Mitsubishi Pharmaceuticals data safety monitoring board member

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1. Canadian Journal of Neurological Sciences, editorial board member, 2006-present; no compensation 2. Turkish Journal of Neurology, editorial board member, 2005-present; no compensation 3. Neurology, editorial board member, 2014-present; no compensation

    Patents:

    1. 1) NMO-IgG for diagnosis of neuromyelitis optica; application 20050112116; patent issued and technology licensed to R.S.R. Ltd.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Elan Pharmaceuticals (2) GlaxoSmithKline Pharmaceuticals (3) Ono Pharmaceuticals (4) Asahi Kasei Medical Company (5) Chugai Pharmaceuticals (6) Alexion Pharmaceuticals (7) Chord Pharmaceuticals

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. (1)Medimmune Pharmaceuticals, Adjudication Committee Member

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation, sponsor of research in NMO, 10/2008-09/2011

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NMO-IgG for diagnosis of neuromyelitis optica; patent issued and technology licensed to R.S.R. Ltd.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. D.M. Wingerchuk, MD and
    13. Scientific Advisory Boards:

    1. (1) Adjudication committee for therapeutic trial, MedImmune

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Current Medical Research and Opinion, Editorial Advisory Board member, 2006-present (2) Drugs in Context, Editorial Advisory Board Member, 2012-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Alexion, (2) Chugai Pharmaceuticals,(3) MedImmune

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Genzyme,(2) Alexion,(3) TerumoBCT

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) National Multiple Sclerosis Society (2) Guthy-Jackson Charitable Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. A. McKeon, MD
    14. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Medimmune, Inc

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Laboratory Medicine and Pathology (J.P.F., V.A.L., S.J.P., E.H., E.A.J., A.M.), Neurology (V.A.L., S.J.P., S.L.C., C.F.L., B.G.W., A.M.), Immunology (V.A.L.), and Health Sciences Research (S.M.J.), College of Medicine, Mayo Clinic, Rochester, MN; Institute of Pathology and Neuropathology (P. F.-B.), University of Tubingen, Germany; Department of Neurology (E.A.S.), College of Medicine, Mayo Clinic, Jacksonville, FL; and Department of Neurology (D.M.W.), College of Medicine, Mayo Clinic, Scottsdale, AZ.
  1. Correspondence to Dr. McKeon: mckeon.andrew{at}mayo.edu
View Full Text

Article usage

Article usage: May 2014 to March 2019

AbstractFullPdfSource
May 201489516Highwire
Jun 201441218198Highwire
Jul 201417114539Highwire
Aug 201412214216Highwire
Sep 2014703915Highwire
Oct 2014702816Highwire
Nov 2014701115Highwire
Dec 2014451517Highwire
Jan 2015342213Highwire
Jan 201504520pmc
Feb 201543710Highwire
Feb 201503725pmc
Mar 2015477011Highwire
Mar 201504021pmc
Apr 201530139Highwire
Apr 201502414pmc
May 201513218Highwire
May 201503219pmc
Jun 201524127Highwire
Jun 201503414pmc
Jul 201537134Highwire
Jul 201502215pmc
Aug 201579189Highwire
Aug 201504021pmc
Sep 20153678Highwire
Sep 201502610pmc
Oct 20151757Highwire
Oct 201501713pmc
Nov 201529612Highwire
Nov 201504424pmc
Dec 20153095Highwire
Dec 201503513pmc
Jan 2016351312Highwire
Jan 201603417pmc
Feb 20163148Highwire
Feb 20160185pmc
Mar 201623217Highwire
Mar 201602517pmc
Apr 201631611Highwire
Apr 20160195pmc
May 20163568Highwire
May 20160175pmc
Jun 201639311Highwire
Jun 201603214pmc
Jul 201638813Highwire
Jul 201603010pmc
Aug 201628810Highwire
Aug 201604011pmc
Sep 2016141011Highwire
Sep 201603014pmc
Oct 201622117Highwire
Oct 201602410pmc
Nov 20161949Highwire
Nov 20160266pmc
Dec 20162273Highwire
Dec 20160235pmc
Jan 20171659Highwire
Jan 20170235pmc
Feb 20171675Highwire
Feb 201702016pmc
Mar 201717107Highwire
Mar 20170216pmc
Apr 20171585Highwire
Apr 201781719pmc
May 201712107Highwire
May 201712943pmc
Jun 20172185Highwire
Jun 201751520pmc
Jul 2017854Highwire
Jul 201721925pmc
Aug 20172195Highwire
Aug 2017131830pmc
Sep 20171333Highwire
Sep 2017122030pmc
Oct 20171666Highwire
Oct 2017111518pmc
Nov 20171448Highwire
Nov 201761621pmc
Dec 2017185Highwire
Jan 20180136Highwire
Feb 201811811Highwire
Mar 20180168Highwire
Apr 201801993Highwire
Apr 201811929pmc
May 201821926Highwire
Jun 201821074Highwire
Jun 201832129pmc
Jul 201811039Highwire
Aug 201843413Highwire
Aug 201882126pmc
Sep 20181329Highwire
Oct 201864311Highwire
Nov 2018110113Highwire
Dec 201834149Highwire
Jan 2019637511Highwire
Feb 2019922315Highwire
Mar 201926016Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement